Novel CAR-T Approach Targets Prostate Cancer's Elusive Molecular Landscape
Researchers are exploring a first-in-human CAR-T cell therapy targeting STEAP2, a promising approach in the challenging terrain of metastatic castration-resistant prostate cancer (mCRPC). The A-CAR032 trial represents an innovative immunotherapeutic strategy designed to address persistent treatment resistance in advanced prostate cancer.
The Phase 1 trial will evaluate a dnTGF-βRII-armoured STEAP2-targeted autologous CAR T-cell injection, enrolling 27 participants with mCRPC who have progressed after standard androgen receptor pathway inhibitor (ARPI) treatments. The study's two-part design includes a dose escalation phase followed by dose expansion, targeting patients with limited therapeutic alternatives.
Research context
Metastatic castration-resistant prostate cancer remains a formidable clinical challenge, with current standard-of-care therapies including ARPIs like abiraterone and enzalutamide offering limited durable responses. Recent therapeutic innovations have expanded treatment options, including PARP inhibitors and radioligand therapies, but significant unmet needs persist.
The STEAP2 target represents a novel molecular approach. Unlike existing therapies that primarily target androgen receptor pathways, this CAR-T strategy aims to directly eliminate cancer cells expressing the Six Transmembrane Epithelial Antigen of the Prostate 2 (STEAP2).